Corpus overview


Overview

MeSH Disease

Human Phenotype

Hypertension (77)

Fever (26)

Cough (22)

Pneumonia (15)

Fatigue (12)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 77
    records per page




    The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study

    Authors: Tarek Sulaiman; Abdulrhman Mohana; Laila Alawdah; Nagla Mahmoud; Mustafa Hassanein; Tariq Wani; Amel Alfaifi; Eissa Alenazi; Nashwa Radwan; Nasser AlKhalifah; Ehab Elkady; Manwer AlAnazi; Mohammed Alqahtani; Khalid Abdalla; Yousif Yousif; Fouad AboGazalah; Fuad Awwad; Khaled AlabdulKareem; Fahad AlGhofaili; Ahmed AlJedai; Hani Jokhdar; Fahad Alrabiah

    doi:10.1101/2020.09.09.20184143 Date: 2020-09-13 Source: medRxiv

    ABSTRACT BACKGROUND: Currently, there is no proven effective therapy nor vaccine for the treatment of SARS-CoV-2. Evidence regarding the potential benefit of early administration of hydroxychloroquine (HCQ) therapy in symptomatic patients with Coronavirus Disease MESHD (COVID-19) is not clear. METHODS: This observational prospective cohort study took place in 238 ambulatory fever HP clinics in Saudi Arabia, which followed the Ministry of Health (MOH) COVID-19 treatment guideline. This guideline included multiple treatment options for COVID-19 based on the best available evidence at the time, among which was Hydroxychloroquine (HCQ). Patients with confirmed COVD-19 (by reverse transcriptase polymerase chain reaction (PCR) test) who presented to these clinics with mild to moderate symptoms during the period from 5-26 June 2020 were included in this study. Our study looked at those who received HCQ-based therapy along with supportive care (SC) and compared them to patients who received SC alone. The primary outcome was hospital admission within 28-days of presentation. The secondary outcome was a composite of intensive care admission (ICU) and/or mortality during the follow-up period. Outcome data were assessed through a follow-up telephonic questionnaire at day 28 and were further verified with national hospitalisation and mortality registries. Multiple logistic regression model was used to control for prespecified confounders. RESULTS: Of the 7,892 symptomatic PCR-confirmed COVID-19 patients who visited the ambulatory fever HP clinics during the study period, 5,541 had verified clinical outcomes at day 28 (1,817 patients in the HCQ group vs 3,724 in the SC group). At baseline, patients who received HCQ therapy were more likely to be males TRANS who did not have hypertension HP hypertension MESHD or chronic lung disease HP lung disease MESHD compared to the SC group. No major differences were noted regarding other comorbid conditions. All patients were presenting with active complaints; however, the HCQ groups had higher rates of symptoms compared to the SC group ( fever HP fever MESHD: 84% vs 66.3, headache HP headache MESHD: 49.8 vs 37.4, cough HP: 44.5 vs 35.6, respectively). Early HCQ-based therapy was associated with a lower hospital admission within 28-days compared to SC alone (9.4% compared to 16.6%, RRR 43%, p-value <0.001). The composite outcome of ICU admission and/or mortality at 28-days was also lower in the HCQ group compared to the SC (1.2% compared to 2.6%, RRR 54%, p-value 0.001). Adjusting for age TRANS, gender TRANS, and major comorbid conditions, a multivariate logistic regression model showed a decrease in the odds of hospitalisation in patients who received HCQ compared to SC alone (adjusted OR 0.57 [95% CI 0.47-0.69], p-value <0.001). The composite outcome of ICU admission and/or mortality was also lower for the HCQ group compared to the SC group controlling for potential confounders (adjusted OR 0.55 [95% CI 0.34-0.91], p-value 0.019). CONCLUSION: Early intervention with HCQ-based therapy in patients with mild to moderate symptoms at presentation is associated with lower adverse clinical outcomes among COVID-19 patients, including hospital admissions, ICU admission, and/or death.

    Clinical Characteristics of Severe Covid Pneumonia HP: Exploring New Trends in ICU

    Authors: Aftab Akhtar; Sheher Bano; Ahtesham Iqbal; Moazma Ramzan; Aayesha Qadeer; Syed Waqar Hussain; Anam Saleem; Omair-ul-Haq Lodhi; Sana Zubair; Abdul Hameed kiani

    doi:10.21203/rs.3.rs-69224/v1 Date: 2020-08-31 Source: ResearchSquare

    Background: In late December 2019, Covid-19 emerged as clusters of pneumonia HP pneumonia MESHD of unknown cause in a province of china, Wuhan. Etiological agent was identified as novel coronavirus that resembles severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East Respiratory syndrome coronavirus (MERS-CoV) MESHD and has zoonotic transmission TRANS. Covid pneumonia HP can remain asymptomatic TRANS, present as mild infection, severe HP infection, severe MESHD pneumonia HP pneumonia MESHD or respiratory failure HP respiratory failure MESHD. Diagnosis is based on rRT-PCR carried out on respiratory secretions. Covid related mortality exceeds 50% once patient requires ICU admission. Objective: To study the characteristics of ICU population admitted to ICU of Shifa International hospital.Results: we prospectively analysed 74 patients which included 43.3% females TRANS and 56.7% males TRANS. Commonest symptoms were shortness of breath MESHD (94.5%), fever HP fever MESHD (74.3%) and cough HP (74.3%). Most of our study population consisted of non-smokers (79.7%) and had hypertension HP hypertension MESHD (59.4%) followed by diabetes MESHD (47.2%). Hydroxychloroquine (HCQ) and azithromycin combination is superior to hydroxychloroquine and doxycycline in reducing mortality (p=0.023) whereas Doxycycline alone resulted in increased mortality (p=0.009). Those who did not require antibiotics or required only narrow spectrum antibiotics had increased survival and reduced requirement of invasive mechanical ventilation (p=< 0.0001). in our study population, (44.9%) developed acute kidney injury HP acute kidney injury MESHD, 2.7% needed re-intubations 10.8% developed surgical emphysema HP emphysema MESHD and 2.7 % thromboembolic MESHD events despite full anticoagulation. ICU mortality was 41.8% and was higher in females TRANS (59.4%, p=0.008), those who had SOFA score > 3.5 at time of admission, raised D-Dimers > 931 ng/ml, NLR > 9.2. It was further high in those who required invasive mechanical ventilation and vasopressor support (58.1% mortality p=< 0.001). ICU stay was more prolonged in those requiring invasive mechanical ventilation as compared to those who did not. (23 days vs 6 days, p=0.001). Mean plateau pressure was 19.6 ± 7.6; mean Driving pressures 14.4 ± 4.6; mean PaO2/FiO2 150.7 ± 73.9; mean SPO2/FiO2 173.9 ± 106.9; mean PEEP was 8.2 ±4.33.Conclusion: We concluded that severe covid pneumonia HP pneumonia MESHD is common amongst males TRANS, non-smokers those who had comorbid. HCQ and azithromycin combination is superior to combination of HCQ and doxycycline or doxycycline alone and QT prolongation MESHD is a rare complication. Baseline NLR, APACHI II, SOFA, SAPS II, NUTRIC scores, D-Dimers, invasive ventilation and vasopressor support are important tools to predict ICU mortality. Invasive mechanical ventilation carries higher mortality and associated with more prolonged ICU stay. AKI is most common complication followed by shock HP and surgical emphysema HP emphysema MESHD. CRP, Ferritin levels has no impact on outcome.

    Clinical characteristics study of elderly TRANS patients aged TRANS 75 or older with COVID-19 pneumonia HP pneumonia MESHD in China

    Authors: Chao Zhang; Hua Fu; Long Zhang; Yuxiong Yin; Jing Lin; Hu Liu; Qing Mao

    doi:10.21203/rs.3.rs-67737/v1 Date: 2020-08-28 Source: ResearchSquare

    Background: Coronavirus disease 2019 (COVID-19), a newly emerged respiratory disease MESHD caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has recently become pandemic. Clinical observation indicated that elderly TRANS patients had high incidence of severe pneumonia HP pneumonia MESHD and poor treatment efficacy. Therefore, this study was to clarify the characteristics of elderly TRANS patients aged TRANS 75 or older with COVID-19 pneumonia HP pneumonia MESHD in order to guide rational treatment for elderly TRANS patients. Methods: we enrolled 331 elderly TRANS patients aged TRANS 75 or older with confirmed COVID-19 in Huoshenshan hospital of Wuhan from February 3rd to March 31st. The cases were divided into general, serious and critical groups according to severity after hospitalization, and the difference among groups were compared by R package statistics software. Results: Compared with general group, serious and critical groups had more underlying comorbidities and higher incidence of cough HP cough MESHD, breath shortness MESHD and anorexia HP anorexia MESHD. Moreover, there existed obviously differences in many of laboratory indexes and CT images among them. serious and critical elderly TRANS patients were more likely to receive oxygen, mechanical ventilation, expectorant, corticosteroid, abidor, cephaloprin, imipenem, human serum SERO albumin (HSA), nutrition support, anti SARS-CoV-2 positive plasma SERO and actemra. Multivariate analysis of factors showed that male TRANS sex, hypertension HP hypertension MESHD, diabetes MESHD, renal diseases MESHD, breath shortness MESHD, neutrophil, platelet, creatinine, lactate dehydrogenase were the risk factor for serious and critical illness. While blood SERO cell (WBC) was the protective factor. Conclusion: elderly TRANS patients have high incidence of severe pneumonia HP pneumonia MESHD and poor treatment efficacy. The reasons might be that many of the elderly TRANS patients with COVID-19 pneumonia HP pneumonia MESHD have certain chronic disease MESHD, poor immune function and a meager response to the virus. the pathogenic mechanism of SARS-CoV-2 might be involved in the cell-mediated immunity and cytokine storms by acting on lymphocytes.

    Clinical Characteristics, Comorbidities, Initial Management and Outcome of COVID-19 Infected Patients Admitted to Intensive Care Unit in Somalia: A National Retrospective Study.

    Authors: Mohamed Farah Yusuf Mohamud; Abdullahi Said Hashi; Abdikarim Hussein Mohamed; Ali Mohamed Yusuf; Ibrahim Hussein Ali; Mohamed Abdi Ahmed

    doi:10.21203/rs.3.rs-66767/v1 Date: 2020-08-27 Source: ResearchSquare

    Purpose: To investigate the clinical characteristics, morbidities, management, and outcomes of COVID-19 Infected patients admitted to the intensive care unit (ICU) in Somalia.Material MESHD and methods: We conducted a retrospective observational study of laboratory 60 confirmed patients with severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) admitted to an ICU from March 28, to May 28, 2020.The sociodemographic characteristics, comorbidities, exposure history, clinical manifestations (symptoms and signs), laboratory findings, treatment, and outcomes were collected from medical records.Results: Most of the patients admitted to ICU were men over 59 years of age TRANS, and nearly half had diabetes MESHD followed by hypertension HP hypertension MESHD chronic kidney disease HP and asthma HP asthma MESHD. The most clinical presentations were dyspnea HP dyspnea MESHD (91.2%), Fever HP Fever MESHD (81.1%), (68.75%), Fatigue HP and myalgia HP myalgia MESHD (25%), and Altered level of conscious (16.6%). Among 48 patients admitted to the ICU, about 24 (50%) patients had required endotracheal intubation and mechanical ventilation, and 11(29.9%) patients needed noninvasive ventilation, while 13(27.08%) patients treated with high-flow oxygen therapy >15 L/min (Table 3). Corticosteroids were administered to most patients (85.4%), while 77.1% of the patients received inhaled bronchodilators and morethan half of the patients administered antibiotics. 58.3% of the patients had received Oseltamivir, while 22.9% received Vasopressors.Conclusion This study represents the first description of critically ill MESHD patients infected with SARS-CoV-2 admitted to ICU in Somalia. The study identified that elder age TRANS, male TRANS gender TRANS, and diabetic MESHD and hypertensive MESHD comorbidities as independent risk factors of poor outcomes for patients admitted to the ICU (p<0.005).

    Observational Study on Clinical Features, Treatment and Outcome of COVID 19 in a tertiary care Centre in India- a retrospective case series

    Authors: Raja Bhattacharya; Rohini Ghosh; Manish Kulshrestha; Sampurna Chowdhury; Rishav Mukherjee; Indranil Ray; Lionel Tim Ee Cheng; Lynette Lin Ean Oon; Min Han Tan; Kian Sing Chan; Li Yang Hsu; Ramgyan Yadav; Ashish Timalsina; Chetan Nidhi Wagle; Brij Kumar Das; Ramesh Kunwar; Binaya Chalise; Deepak Raj Bhatta; Mukesh Adhikari; Michael Gale; Daniel J Campbell; David Rawlings; Marion Pepper

    doi:10.1101/2020.08.12.20170282 Date: 2020-08-14 Source: medRxiv

    ABSTRACT Objective: This study will attempt to explore the demographic profile and outcome in the patients receiving multidisciplinary, personalised approach including use of Broad Spectrum Antivirals - Ivermectin, anti-inflammatory and antioxidants roles of Statins and N-acetyl-cysteine along with Standard of Care (SOC) in hospitalised COVID19 patients in a tertiary care centre. Setting: Inpatient department Participants: 191 COVID-19 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections MESHD in the year 2020 between June 14- 28, 2020 Main outcome measures: The outcome of Interests are : Studying the demographic profile of COVID 19 cases Study the treatment outcomes in terms of death MESHD or discharge in patients receiving Ivermectin+N-acetyl-cysteine+Statin along with Standard of care. Results: 148 patients were included in the study. All of them had confirmed COVID19 infection MESHD by the rtPCR method. Average age TRANS of the patients was 57.57 years ( Range = 17 - 88), 49% were male TRANS, 51% female TRANS. 81% of the patients had at least one or more comorbidities. Most common comorbidities included diabetes MESHD( 32%), Hypertension HP Hypertension MESHD (27%), Ischaemic Heart Disease MESHD (8%). More comorbidities. The in hospital, Case Fatality Rate was therefore, 1.35 %. The remaining 144 were discharged from the facility after an average 12 days duration of stay. Conclusions: Triple therapy with ivermectin + atorvastatin + N-acetylcysteine can be an useful adjunct to standard of care. Keywords: SARS-CoV-2, COVID-19, outpatients, treatment, zinc, hydroxychloroquine, azithromycin

    Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease MESHD 2019: A Systematic Review and Meta-Analysis

    Authors: Vignesh Chidambaram; Nyan Lynn Tun; Waqas Haque; Marie Gilbert Majella; Ranjith Kumar Sivakumar; Amudha Kumar; Angela Ting-Wei Hsu; Izza Ishak; Aqsha Nur; Samuel Ayeh; Emmanuella Salia; Ahsan Zil-E-Ali; Muhammad Saeed; Ayu Sarena; Bhavna Seth; Muzzammil Ahmadzada; Eman Haque; Pranita Neupane; Kuang-Heng Wang; Tzu-Miao Pu; Syed Ali; Muhammad Arshad; Lin Wang; Sheriza Baksh; Petros Karakousis; Panagis Galiatsatos

    doi:10.1101/2020.08.07.20166868 Date: 2020-08-13 Source: medRxiv

    Background: Understanding the factors associated with disease severity and mortality in Coronavirus disease MESHD (COVID19) is imperative to effectively triage patients. We performed a systematic review to determine the demographic, clinical, laboratory and radiological factors associated with severity and mortality in COVID-19. Methods: We searched PubMed, Embase and WHO database for English language articles from inception until May 8, 2020. We included Observational studies with direct comparison of clinical characteristics between a) patients who died and those who survived or b) patients with severe disease and those without severe disease. Data extraction and quality assessment were performed by two authors independently. Results: Among 15680 articles from the literature search, 109 articles were included in the analysis. The risk of mortality was higher in patients with increasing age TRANS, male TRANS gender TRANS (RR 1.45; 95%CI 1.23,1.71), dyspnea HP dyspnea MESHD (RR 2.55; 95%CI 1.88,2.46), diabetes MESHD (RR 1.59; 95%CI 1.41,1.78), hypertension HP hypertension MESHD (RR 1.90; 95%CI 1.69,2.15). Congestive heart failure HP Congestive heart failure MESHD (OR 4.76; 95%CI 1.34,16.97), hilar lymphadenopathy HP lymphadenopathy MESHD (OR 8.34; 95%CI 2.57,27.08), bilateral lung involvement (OR 4.86; 95%CI 3.19,7.39) and reticular pattern (OR 5.54; 95%CI 1.24,24.67) were associated with severe disease. Clinically relevant cut-offs for leukocytosis HP leukocytosis MESHD(>10.0 x109/L), lymphopenia HP lymphopenia MESHD(< 1.1 x109/L), elevated C-reactive protein(>100mg/L), LDH(>250U/L) and D-dimer(>1mg/L) had higher odds of severe disease and greater risk of mortality. Conclusion: Knowledge of the factors associated of disease severity and mortality identified in our study may assist in clinical decision-making and critical-care resource allocation for patients with COVID-19.

    Clinical Determinants of the Severity of Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review and Meta-Analysis

    Authors: Yanling Wu; Hu Li; Shengjin Li

    doi:10.21203/rs.3.rs-56852/v1 Date: 2020-08-10 Source: ResearchSquare

    Background: SARS-CoV-2 is an emerging pathogen, and coronavirus disease MESHD 2019 (COVID-19) has been declared a global pandemic. We aim to summarize current evidence regarding the risk of death MESHD and the severity of COVID-19 as well as risk factors for severe COVID-19.Methods: The PubMed, Embase, and Web of Science databases as well as some Chinese databases were searched for clinical and epidemiological studies on COVID-19. We conducted a meta-analysis to examine COVID-19-related death MESHD and risk factors for the severity of COVID-19.Results: A total of 55 studies fulfilled the criteria for this review. The case fatality risk ranged from 0 to 61.5%, with a pooled estimate of 3.3%. The risks of ICU admission, acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD)and severe COVID-19 were 24.9%, 20.9% and 26.6%, respectively. Factors related to the risk of severe COVID-19 were older age TRANS (MD=10.09, 95% CI:7.03, 13.16), male TRANS sex (OR=1.62, 95% CI:1.32, 1.99), hypertension HP hypertension MESHD (OR=2.34, 95% CI:1.47, 3.73), diabetes MESHD (OR=2.25, 95% CI:1.68, 3.03), chronic renal disease MESHD (OR=3.60, 95% CI:1.53, 8.46), heart disease MESHD (OR=2.76, 95% CI:1.78, 4.30), respiratory disease MESHD (OR=3.74, 95% CI:2.15, 6.49), cerebrovascular disease MESHD (OR=2.21, 95% CI:1.23, 3.98), higher D-dimer levels (SMD=0.62, 95% CI:0.28, 0.96), and higher IL-6 levels (SMD=2.21, 95% CI:0.11, 4.31). However, liver disease MESHD (OR=0.63, 95% CI: 0.36, 1.10) was found to be a nonsignificant predictor of the severity of COVID-19.Conclusions: The case fatality risk of COVID-19 and the risk of severe manifestations were not very high, and variances in the study designs and regions led to high heterogeneity among the studies. Male TRANS sex, older age TRANS, comorbidities such as hypertension HP hypertension MESHD, diabetes MESHD, cardiovascular disease MESHD, respiratory disease MESHD and cerebrovascular disease MESHD could increase the risk of developing a severe case of COVID-19. Laboratory parameters, such as D-dimer and IL-6 levels, could affect the prognosis of COVID-19.

    Impact of tocilizumab administration on mortality in severe COVID-19

    Authors: Andrew Tsai; Oumou Diawara; Ronald G Nahass; Luigi Brunetti

    doi:10.1101/2020.07.30.20114959 Date: 2020-08-02 Source: medRxiv

    Background The novel coronavirus disease MESHD 2019 (COVID-19) worldwide pandemic has placed a significant burden on hospitals and healthcare providers. The immune response to this disease is thought to lead to a cytokine storm, which contributes to the severity of illness. There is an urgent need to confirm whether the use of tocilizumab provides a benefit in individuals with COVID-19. Methods A single-center propensity-score matched cohort study, including all consecutive COVID-19 patients, admitted to the medical center who were either discharged from the medical center or expired between March 1, 2020, and May 5, 2020, was performed. Patients were stratified according to the receipt of tocilizumab for cytokine storm and matched to controls using propensity scores. The primary outcome was in-hospital mortality. Results A total of 132 patients were included in the matched dataset (tocilizumab=66; standard of care=66). Approximately 73% of the patients were male TRANS. Hypertension HP Hypertension MESHD (55%), diabetes mellitus HP diabetes mellitus MESHD (31%), and chronic pulmonary disease MESHD (15%) were the most common comorbidities present. There were 18 deaths (27.3%) in the tocilizumab group and 18 deaths (27.3%) in the standard of care group (odds ratio, 1.0; 95% confidence interval, 0.465 - 2.151; p=1.00). Advanced age TRANS, history of myocardial infarction HP myocardial infarction MESHD, dementia HP dementia MESHD, chronic pulmonary disease MESHD, heart failure MESHD, and malignancy MESHD were significantly more common in patients who died. Interpretation The current analysis does not support the use of tocilizumab for the management of cytokine storm in patients with COVID-19. Use of this therapeutic agent should be limited to the context of a clinical trial until more evidence is available.

    Clinical manifestations of patients with Coronavirus Disease MESHD 2019 (COVID- 19) attending at hospitals in Bangladesh

    Authors: Md. Shahed Morshed; Abdullah Al Mosabbir; Prodipta Chowdhury; Sheikh Mohammad Ashadullah; Mohammad Sorowar Hossain

    doi:10.1101/2020.07.30.20165100 Date: 2020-08-01 Source: medRxiv

    Bangladesh is in the rising phase of the ongoing pandemic of the coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 MESHD (SARS-CoV-2). The scientific literature on clinical manifestations of COVID-19 patients from Bangladesh is scarce. This study aimed to report the sociodemographic and clinical characteristics of patients with COVID-19 in Bangladesh. We conducted a cross-sectional study at three dedicated COVID-19 hospitals. The severity of the COVID-19 cases was assessed based on the WHO interim guidance. Data were collected only from non-critical COVID-19 patients as critical patients required immediate intensive care admission making them unable to respond to the questions. A total of 103 RT-PCR confirmed non-critical COVID-19 patients were enrolled. Most of the patients (71.8%) were male TRANS. Mild, moderate and severe illness were assessed in 74.76%, 9.71% and 15.53% of patients respectively. Nearly 52.4% of patients had a co-morbidity, with hypertension HP hypertension MESHD being the most common (34%), followed by diabetes mellitus HP diabetes mellitus MESHD (21.4%) and ischemic MESHD heart disease MESHD (9.7%). Fever HP Fever MESHD (78.6%), weakness MESHD (68%) and cough HP (44.7%) were the most common clinical manifestations. Other common symptoms included loss of appetite (37.9%), difficulty in breathing (37.9%), altered sensation of taste or smell (35.0%), headache HP headache MESHD (32%) and body ache MESHD (32%). The median time from onset of symptom TRANS to attending hospitals was 7 days (IQR 4-10). This study will help both the clinicians and epidemiologists to understand the magnitude and clinical spectrum of COVID-19 patients in Bangladesh.

    Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System

    Authors: Jean Y. Ko; Melissa L. Danielson; Machell Town; Gordana Derado; Kurt J. Greenland; Pam Daily Kirley; Nisha B. Alden; Kimberly Yousey-Hindes; Evan J. Anderson; Patricia A. Ryan; Sue Kim; Ruth Lynfield; Salina M. Torres; Grant R. Barney; Nancy M. Bennett; Melissa Sutton; H. Keipp Talbot; Mary Hill; Aron J. Hall; Alicia M. Fry; Shikha Garg; Lindsay Kim; - COVID-NET Investigation Group

    doi:10.1101/2020.07.27.20161810 Date: 2020-07-29 Source: medRxiv

    Background: Identification of risk factors for COVID-19-associated hospitalization is needed to guide prevention and clinical care. Objective: To examine if age TRANS, sex, race/ethnicity, and underlying medical conditions is independently associated with COVID-19-associated hospitalizations. Design: Cross-sectional. Setting: 70 counties within 12 states participating in the Coronavirus Disease MESHD 2019-Associated Hospitalization Surveillance Network (COVID-NET) and a population-based sample of non-hospitalized adults TRANS residing in the COVID-NET catchment area from the Behavioral Risk Factor Surveillance System. Participants: U.S. community-dwelling adults TRANS ([≥]18 years) with laboratory-confirmed COVID-19-associated hospitalizations, March 1- June 23, 2020. Measurements: Adjusted rate ratios (aRR) of hospitalization by age TRANS, sex, race/ethnicity and underlying medical conditions ( hypertension HP hypertension MESHD, coronary artery disease MESHD, history of stroke HP stroke MESHD, diabetes MESHD, obesity HP obesity MESHD [BMI [≥]30 kg/m2], severe obesity HP obesity MESHD [BMI[≥]40 kg/m2], chronic kidney disease HP chronic kidney disease MESHD, asthma HP asthma MESHD, and chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD). Results: Our sample included 5,416 adults TRANS with COVID-19-associated hospitalizations. Adults TRANS with (versus without) severe obesity HP obesity MESHD (aRR:4.4; 95%CI: 3.4, 5.7), chronic kidney disease HP chronic kidney disease MESHD (aRR:4.0; 95%CI: 3.0, 5.2), diabetes MESHD (aRR:3.2; 95%CI: 2.5, 4.1), obesity HP obesity MESHD (aRR:2.9; 95%CI: 2.3, 3.5), hypertension HP hypertension MESHD (aRR:2.8; 95%CI: 2.3, 3.4), and asthma HP asthma MESHD (aRR:1.4; 95%CI: 1.1, 1.7) had higher rates of hospitalization, after adjusting for age TRANS, sex, and race/ethnicity. In models adjusting for the presence of an individual underlying medical condition, higher hospitalization rates were observed for adults TRANS [≥]65 years, 45-64 years (versus 18-44 years), males TRANS (versus females TRANS), and non-Hispanic black and other race/ethnicities (versus non-Hispanic whites). Limitations: Interim analysis limited to hospitalizations with underlying medical condition data. Conclusion: Our findings elucidate groups with higher hospitalization risk that may benefit from targeted preventive and therapeutic interventions.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.